Climb Bio Inc (CLYM) Quarterly Institutional 13F Update (Q2 2026)

CLYM ranks #4356 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

111 institutions disclose a position in CLYM, but none treat it as a major bet — even Superstring Capital Management LP, its most concentrated holder, allocates just 4.3% of its own portfolio to it.

Fidelity has added to its CLYM position for two straight quarters, increasing it by $88.5M to reach $88.5M today.

Two Sigma Investments, LP has trimmed its CLYM position for two straight quarters, cutting it by $333.8K while still holding $1.9M.

CLYM is up 1.6% today, and institutions have been net buyers of $396.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CLYM reported a net loss of $59.9M in its latest fiscal year.

• Not yet profitable — net loss of $59.9M in the latest fiscal year
• Net income improved year over year, from -$73.9M to -$59.9M
• Operating cash flow was negative, using $54.4M in cash
• Current ratio of 15.16x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range